Elucidation of a novel mechanism of action of ropinirole hydrochloride

「This is a research result concerning the mechanism of action of ropinirole hydrochloride in ALS, obtained through joint research with the research group of Professor Hideyuki Okano of Keio University.」

「On 18 August 2025 (U.S. time), a paper titled “Ropinirole functions through a dopamine receptor D2-independent mechanism to ameliorate amyotrophic lateral sclerosis phenotypes in TARDBP-mutant iPSC-derived motor neurons” was published in the international academic journal Journal of Neurochemistry. The paper reports research findings on the mechanism of action of ropinirole hydrochloride in ALS, obtained through joint research with the research group of Professor Okano Hideyuki (岡野 栄之) of Keio University.」

「1) Elucidation of the mechanism of action of ropinirole hydrochloride in ALS; 2) iPS cell-based drug discovery for intractable neurological diseases; 3) joint research on regenerative medicine using iPS cells.」

「In parallel with our alliance with Alfresa Pharma Corporation, we are conducting research and development with Keio University to establish clearly that ropinirole hydrochloride is a novel drug that produces therapeutic effects against ALS through a novel mechanism.」

「In joint research with Keio University, we are working to establish clearly that ropinirole hydrochloride is a novel drug that produces therapeutic effects against ALS through a novel mechanism.」